Sulindac. Trials of a new anti-inflammatory drug
- PMID: 343728
- PMCID: PMC1000199
- DOI: 10.1136/ard.37.1.89
Sulindac. Trials of a new anti-inflammatory drug
Abstract
Trials in patients with rheumatoid arthritis and osteoarthritis showed sulindac to be an analgesic with anti-inflammatory properties and at least as effective as aspirin. It was effective within 24 hours in doses of 300-400 mg daily. It had the advantages of twice daily administration and a lower incidence of gastric side effects than aspirin. Constipation, usually mild, occurred in 20-30% of cases. Like other anti-inflammatory drugs, it was effective in only a proportion of the patients.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
